The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Impact of minimal residual disease (MRD) status in clinical outcomes of patients with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL) treated with inotuzumab ozogamicin (InO) in the phase 3 INO-VATE trial.
 
Elias Jabbour
Consulting or Advisory Role - Pfizer
Research Funding - Pfizer
 
Nicola Gökbuget
Honoraria - Pfizer
Consulting or Advisory Role - Pfizer
Research Funding - Pfizer (Inst)
 
Anjali S. Advani
Honoraria - EUSA Pharma; Pfizer; Sigma-Tau
Consulting or Advisory Role - Glycomimetics; Novartis; Pfizer; Seagen
Research Funding - KaloBios (Inst); Millennium (Inst); Pfizer (Inst); Seagen (Inst)
 
Matthias Stelljes
No Relationships to Disclose
 
Wendy Stock
Honoraria - ADC Therapeutics; amgen; Gilead Sciences; Pfizer
Research Funding - Sigma-Tau (Inst)
Patents, Royalties, Other Intellectual Property - Royalties for a chapter in Up to Date
 
Michaela Liedtke
Honoraria - Amgen; Pfizer; Prothena
Consulting or Advisory Role - Amgen; Caelum Biosciences; Pfizer; Prothena; Takeda
Research Funding - Amgen (Inst); Bluebird Bio (Inst); Celgene (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); Pfizer (Inst); Prothena (Inst); Takeda (Inst)
 
Giovanni Martinelli
Consulting or Advisory Role - ARIAD; Celgene; Pfizer; Roche
Speakers' Bureau - Bristol-Myers Squibb; Novartis
 
Susan Mary O'Brien
Employment - University of California, Irvine
Honoraria - Abbvie; Alexion Pharmaceuticals; Amgen; Aptose Biosciences; Astellas Pharma; Celgene; Eisai; Gilead Sciences; GlaxoSmithKline; Janssen; Loxo; Pfizer; Pharmacyclics; Sunesis Pharmaceuticals; TG Therapeutics; Vaniam Group
Consulting or Advisory Role - Abbvie/Genentech; Alexion Pharmaceuticals; Amgen; Amgen Astellas BioPharma; Aptose Biosciences; Celgene; CLL Global Research Foundation; Eisai; GlaxoSmithKline; Janssen Oncology; Loxo; Pharmacyclics; Sunesis Pharmaceuticals; Vaniam Group
Research Funding - Acerta Pharma; Gilead Sciences; Pfizer; Pharmacyclics; ProNAI; Regeneron; TG Therapeutics (Inst)
Travel, Accommodations, Expenses - Celgene; Gilead Sciences; Janssen; Janssen Oncology; Regeneron
 
Tao Wang
Employment - Pfizer
Stock and Other Ownership Interests - Pfizer
 
Douglas Laird
Employment - Pfizer
Stock and Other Ownership Interests - Pfizer
 
Erik Vandendries
Employment - Pfizer
Stock and Other Ownership Interests - Pfizer
 
Alexander Neuhof
Employment - Pfizer
Stock and Other Ownership Interests - Pfizer
 
Daniel J. DeAngelo
Consulting or Advisory Role - Amgen; ARIAD; Bristol-Myers Squibb; Celgene; Immunogen; Incyte; Novartis; Pfizer; Shire
 
Hagop M. Kantarjian
Honoraria - Abbvie; Amgen; ARIAD; Bristol-Myers Squibb; Immunogen; Orsenix; Pfizer
Research Funding - Amgen (Inst); ARIAD (Inst); Astex Pharmaceuticals (Inst); Bristol-Myers Squibb (Inst); Novartis (Inst); Pfizer (Inst)